AstraZeneca Pharma India Q1 FY27: Revenue Up 30% to ₹683 Cr, Three Approvals, and a ₹148.66 Cr Demand Notice

General information and education, not investment advice. The author is not a SEBI-registered adviser or research analyst. No recommendation, no promised returns. Markets carry risk including loss of capital. Figures may not be current. Always consult a SEBI-registered adviser.

1. At a Glance

Quarterly revenue of ₹682.79 crore, up 29.7% from ₹526.31 crore a year earlier — the tenth consecutive quarter in which this company’s top line has behaved like it has somewhere to be. Operating profit for the same quarter: ₹48.94 crore, against ₹81.11 crore in June 2025. Net profit ₹37.93 crore, versus ₹55.83 crore. EPS ₹15.17.

So the revenue line and the profit line spent the quarter walking in opposite directions with great conviction, and the space between them is where the whole entry lives.

Elsewhere in the eventfulness: three regulatory approvals announced in the quarter, an MoU with the Government of Telangana for AI-enabled lung cancer screening, an AGM on 10 August that approved a ₹36 per share dividend, a CFO moving to a regional role within the group, a new Additional Director arriving from Asia Area, and — filed on 30 July — a demand notice from the National Pharmaceutical Pricing Authority for ₹148.66 crore covering a period stretching back to May 2016. For a company whose entire quarterly profit is ₹37.93 crore, that notice is a number worth looking at closely, which we will.

Full-year FY26 revenue was ₹2,275.58 crore with net profit of ₹187.52 crore. Market cap sits at ₹18,539 crore. Promoter holding: 75.00%, unmoved, as it has been every single quarter on record.

2. Introduction

AstraZeneca Pharma India Limited is the listed Indian operating arm of AstraZeneca plc, the multinational headquartered in England that most of the planet learned the name of during the pandemic via the Oxford-AstraZeneca vaccine. AstraZeneca Pharmaceuticals AB holds 75% of the shareholding, which means the free float here is a quarter of a company — a structure that produces the pleasing spectacle of a ₹18,539 crore market capitalisation resting on a share register where the largest holder has never once changed its mind by a single basis point.

The company describes itself as engaged in the manufacture, distribution and marketing of pharmaceutical products, which is the corporate equivalent of describing a symphony as “organised air.” The registered office is at Manyata Embassy Business Park in Bengaluru, and the 47th AGM was held on 10 August 2026 — the forty-seventh, which is a reminder that this listing has been filing paperwork in India since before most of its current oncology portfolio was a molecule anyone had drawn.

The recent institutional history has a specific shape. Per the filings, the company announced in an earlier year an intention to exit its Bangalore manufacturing site; it explored selling the site as a going concern to a contract manufacturer; on 21 June 2024 the Board instead resolved to find a buyer and exit in due course; and during the quarter ended 30 June 2025, operations at the site ceased. The company is now in the process of selling the related assets. Exceptional items in the current quarter — ₹2.4 million — are closure costs from that same exit, meaning this is a factory that is still generating line items after it stopped generating tablets.

Employee count tells its own arc: 1,587 permanent employees at end-FY16, and 802 at end-FY25. The August 2026 press release describes a workforce of over 600 employees across the country.

3. Business Model: WTF Do They Even Do?

They sell prescription medicines, mostly imported, mostly expensive, mostly to people who have received news they did not want.

The portfolio runs under brands including Brilinta, Forxiga, Crestor, Tagrisso, Calquence, Zoladex and Symbicort, spanning Cardiovascular-Renal-Metabolic disease, Oncology, Respiratory and Immunology. The FY23 geographical split was India 94%, exports 6% — this is a company selling into its own postcode.

The therapy mix is where the business has quietly rebuilt itself. Per the disclosed splits, CVRM (cardiovascular plus diabetes) accounted for 75.60% of product sales in the earliest year disclosed and 26.10% in the latest; oncology moved from 22.70% to 69.50% across the same span. That is not a pivot, that is a full corporate personality transplant conducted in public over roughly six years. Oncology’s rank in the Indian pharmaceutical market is disclosed as third; overall IPM rank by revenue moved from 49 to 40 across the three years disclosed.

The Q1 FY27 press release splits the quarter’s revenue by therapy area: Oncology ₹4,649 million growing 26%, Biopharmaceuticals (CVRM, R&I and V&I) ₹1,619 million growing 36%, and Rare Diseases ₹144 million growing — per the company’s own table — 35x. Thirty-five times. Rare Diseases has gone from a rounding error to a slightly larger rounding error, and it did so with the kind of percentage that only exists when the denominator was previously embarrassing.

Mechanically, with manufacturing wound down, the operation increasingly looks like this: import approved molecules, clear them through CDSCO, and put them in front of oncologists. The expense line agrees — purchase of stock-in-trade in the quarter was ₹3,046.2 million against cost of materials consumed of ₹94.9 million. The cost of goods here is largely the cost of buying goods.

4. Financials Overview

Figures are consolidated, in ₹ crore.

Operating margin for the quarter works out at 7% of sales, against 15% in the June 2025 quarter. Expenses rose to ₹633.85 crore from ₹445.20 crore. Within the disclosed expense detail, employee benefit expense was ₹791.6 million against ₹644.5 million a year ago; selling, marketing and distribution ₹307.5 million against ₹220.2 million; and finance